Reverse dilation and redefine your patient experience.
Indication
RYZUMVI (phentolamine ophthalmic solution) 0.75% reverse mydriatic is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
Select important safety information
Warnings and precautions:
- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- Potential for eye injury or contamination: Care should be taken to avoid touching the vial tip to the eye or to any other surface.
- Use with contact lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
- Adverse Reactions: The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).
- Keeler is an authorized distributor of RYZUMVI in the USA.
- RYZUMVI and the Ryzumvi Logo are trademarks of Ocuphire Pharma Inc., licensed to the Viatris Companies.
- Paremyd® is a registered trademark of Akorn Operating Company LLC.
